NASDAQ:VXRT - Vaxart Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.95 -0.15 (-7.14 %) (As of 01/18/2019 04:00 PM ET)Previous Close$2.10Today's Range$1.93 - $2.1652-Week Range$1.65 - $9.46Volume79,249 shsAverage Volume101,749 shsMarket Capitalization$15.64 millionP/E RatioN/ADividend YieldN/ABeta0.57 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California. Receive VXRT News and Ratings via Email Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A Webwww.vaxart.com Phone650-550-3500Debt Debt-to-Equity Ratio0.15 Current Ratio2.39 Quick Ratio2.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$8.90 million Price / Sales1.56 Cash FlowN/A Price / Cash FlowN/A Book Value($11.02) per share Price / Book-0.18Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,400,000.00 Net Margins-330.79% Return on Equity-198.56% Return on Assets-40.81%Miscellaneous Employees16 Outstanding Shares7,141,000Market Cap$15.64 million OptionableNot Optionable Vaxart (NASDAQ:VXRT) Frequently Asked Questions What is Vaxart's stock symbol? Vaxart trades on the NASDAQ under the ticker symbol "VXRT." When did Vaxart's stock split? How did Vaxart's stock split work? Vaxart shares reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split. How were Vaxart's earnings last quarter? Vaxart Inc (NASDAQ:VXRT) posted its earnings results on Friday, November, 9th. The biotechnology company reported ($0.92) earnings per share for the quarter. The biotechnology company earned $0.28 million during the quarter. Vaxart had a negative return on equity of 198.56% and a negative net margin of 330.79%. View Vaxart's Earnings History. When is Vaxart's next earnings date? Vaxart is scheduled to release their next quarterly earnings announcement on Tuesday, February 5th 2019. View Earnings Estimates for Vaxart. Has Vaxart been receiving favorable news coverage? Headlines about VXRT stock have been trending positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vaxart earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future. Who are some of Vaxart's key competitors? Some companies that are related to Vaxart include Outlook Therapeutics (OTLK), BioCardia (BCDA), Applied Genetic Technologies (AGTC), AVITA MED LTD/S (AVMXY), Genocea Biosciences (GNCA), Proteon Therapeutics (PRTO), Arsanis (ASNS), Oncobiologics (ONS), Entera Bio (ENTX), Curis (CRIS), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), TRACON Pharmaceuticals (TCON), CytRx (CYTR) and Vical (VICL). Who are Vaxart's key executives? Vaxart's management team includes the folowing people: Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO & Director (Age 62)Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)Mr. John M. Harland M.B.A., CPA, CFO, Treasurer & Sec. (Age 67)Mr. Brant Biehn, Sr. VP of Commercial OperationsDr. David N. Taylor, Chief Medical Officer (Age 70) How do I buy shares of Vaxart? Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Vaxart's stock price today? One share of VXRT stock can currently be purchased for approximately $1.95. How big of a company is Vaxart? Vaxart has a market capitalization of $15.64 million and generates $8.90 million in revenue each year. Vaxart employs 16 workers across the globe. What is Vaxart's official website? The official website for Vaxart is http://www.vaxart.com. How can I contact Vaxart? Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected] MarketBeat Community Rating for Vaxart (NASDAQ VXRT)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 167 (Vote Outperform)Underperform Votes: 165 (Vote Underperform)Total Votes: 332MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote "Outperform" if you believe VXRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?